Market Overview:
The global chemotherapy-induced thrombocytopenia therapeutics market is expected to register a CAGR of 7.5% during the forecast period, 2018–2030. The market growth can be attributed to the increasing incidence of cancer, rising geriatric population, and technological advancements in the field of chemotherapy-induced thrombocytopenia therapeutics. Based on type, the global chemotherapy-induced thrombocytopenia therapeutics market is segmented into thrombopoietin receptor agonists, thrombopoietic agents, and others. Thrombopoietin receptor agonists are further subsegmented into erythropoiesis stimulating agents (ESAs) and pegylated recombinant human megakaryocyte growth factor (PEG-rhMkGf). The ESA subsegment is expected to account for a major share of the global chemotherapy-induced throm bocytopenia therapeutics market during the forecast period. This can be attributed to their high efficacy in restoring platelet count as compared to other types of drugs available in this category.
Product Definition:
Chemotherapy-induced thrombocytopenia (CIT) is a complication associated with the use of chemotherapy. Chemotherapy can cause a decrease in the number of platelets, which are cells that help blood to clot. This can lead to an increased risk for bleeding.
Thrombopoietin Receptor Agonists:
Thrombopoietin receptor agonists are drugs that stimulate thrombopoietin production by the body. Thrombopoietin is a protein made in the kidney, when it is not enough there may be a problem with blood clotting. The main function of thrombopoietin is to help maintain normal blood coagulation and fibrinolysis (the process of breaking down clots) in the body.
Thrombopoietic Agents:
Thrombopoietic agents are the drugs that act to stimulate or inhibit the platelet aggregation and/or coagulation. The thrombopoietic agents market is segmented on the basis of drug class into, rheumatoid factor (RF), anticoagulants, fibrinolytic agent and anti-platelet agent.
Application Insights:
The other applications segment includes cancer treatment centers and research institutes. The chemotherapy-induced thrombocytopenia therapeutics are used in the treatment of various cancers, which include Non-small Cell Lung Cancer (NSCLC), Breast Cancer, Cervical Cancer, Uterine Sarcoma, Leukemia & Lymphoma among others.
The hospitals segment dominated the global chemotherapy-induced thrombocytopenia therapeutics market in 2017 owing to factors such as presence of a large patient base with different types of cancer and increasing R&D initiatives by companies for developing new drugs specific for treating various cancers. Chemotherapy induced platelet depletion is one of the most common side effects reported during treatments for different types of cancers; therefore this condition leads to increased risk factor exposure which may result in development of secondary malignancies or premature death in patients suffering from solid tumors like NSCLR or breast carcinoma undergoing chemo therapy.
Regional Analysis:
North America dominated the global chemotherapy-induced thrombocytopenia therapeutics market with a revenue share of over 40% in 2017. This is due to the presence of well-established healthcare infrastructure, high patient awareness levels coupled with relatively higher healthcare expenditure levels in this region as compared to other regions. In addition, increasing R&D activities by various pharmaceutical companies for development of novel drugs targeting different pathways and targets involved is one major factor responsible for its dominance. For instance, Pfizer Inc., in collaboration with University College London (UCL) has completed phase 3 clinical trial program investigating combination therapy using Revlimid and Thalomid (somatostatin analog) which are two FDA approved drugs used for CIT treatment respectively.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the chemotherapy-induced thrombocytopenia therapeutics market. According to the American Cancer Society, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S., and approximately 595,690 people died from this disease. This number is expected to rise in the coming years due to growing population and aging population.
- Rising prevalence of chemotherapy-induced thrombocytopenia: The rising prevalence of chemotherapy-induced thrombocytopenia is another key growth driver for this market. Chemotherapy-induced thrombocytopenia occurs when patients receiving chemotherapy develop a low platelet count (thrombocytopenia). This condition can lead to serious health complications such as bleeding and infection if not treated properly.
- Growing demand for novel therapies: The growing demand for novel therapies is another key growth driver for this market as patients are increasingly seeking better treatment options that can improve their quality of life significantly while reducing side effects associated with traditional treatments such as chemotherapy drugs..
Scope Of The Report
Report Attributes
Report Details
Report Title
Chemotherapy-induced Thrombocytopenia Therapeutics Market Research Report
By Type
Thrombopoietin Receptor Agonists, Thrombopoietic Agents, Others
By Application
Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Amgen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd, Mylan N.V., Pfizer Inc, Janssen Global Services, LLC, Partner Therapeutics, Inc, Mission Pharmacal Company, Myelo Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd, Dova Pharmaceuticals, Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Report Segments:
The global Chemotherapy-induced Thrombocytopenia Therapeutics market is segmented on the basis of:
Types
Thrombopoietin Receptor Agonists, Thrombopoietic Agents, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Mylan N.V.
- Pfizer Inc
- Janssen Global Services, LLC
- Partner Therapeutics, Inc
- Mission Pharmacal Company
- Myelo Therapeutics GmbH
- Jiangsu HengRui Medicine Co., Ltd
- Dova Pharmaceuticals, Inc
Highlights of The Chemotherapy-induced Thrombocytopenia Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
- Others
- By Application:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chemotherapy-induced Thrombocytopenia Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chemotherapy-induced thrombocytopenia therapeutics (CITs) are medications that help to prevent or treat chemotherapy-induced thrombocytopenia. CITs can be used in combination with other treatments for chemotherapy-induced thrombocytopenia, such as platelet transfusions and blood products.
Some of the key players operating in the chemotherapy-induced thrombocytopenia therapeutics market are Amgen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd, Mylan N.V., Pfizer Inc, Janssen Global Services, LLC, Partner Therapeutics, Inc, Mission Pharmacal Company, Myelo Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd, Dova Pharmaceuticals, Inc.
The chemotherapy-induced thrombocytopenia therapeutics market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chemotherapy-induced Thrombocytopenia Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chemotherapy-induced Thrombocytopenia Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chemotherapy-induced Thrombocytopenia Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chemotherapy-induced Thrombocytopenia Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Chemotherapy-induced Thrombocytopenia Therapeutics Market Size and Y-o-Y Growth
4.5.2 Chemotherapy-induced Thrombocytopenia Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Type
5.2.1 Thrombopoietin Receptor Agonists
5.2.2 Thrombopoietic Agents
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Applications
6.2.1 Hospitals Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chemotherapy-induced Thrombocytopenia Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Type
9.6.1 Thrombopoietin Receptor Agonists
9.6.2 Thrombopoietic Agents
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Applications
9.10.1 Hospitals Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Type
10.6.1 Thrombopoietin Receptor Agonists
10.6.2 Thrombopoietic Agents
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Applications
10.10.1 Hospitals Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Type
11.6.1 Thrombopoietin Receptor Agonists
11.6.2 Thrombopoietic Agents
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Applications
11.10.1 Hospitals Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Type
12.6.1 Thrombopoietin Receptor Agonists
12.6.2 Thrombopoietic Agents
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Applications
12.10.1 Hospitals Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chemotherapy-induced Thrombocytopenia Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Type
13.6.1 Thrombopoietin Receptor Agonists
13.6.2 Thrombopoietic Agents
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chemotherapy-induced Thrombocytopenia Therapeutics Market Size Forecast by Applications
13.10.1 Hospitals Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chemotherapy-induced Thrombocytopenia Therapeutics Market: Competitive Dashboard
14.2 Global Chemotherapy-induced Thrombocytopenia Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen Inc.
14.3.2 Novartis AG
14.3.3 Teva Pharmaceutical Industries Ltd
14.3.4 Mylan N.V.
14.3.5 Pfizer Inc
14.3.6 Janssen Global Services, LLC
14.3.7 Partner Therapeutics, Inc
14.3.8 Mission Pharmacal Company
14.3.9 Myelo Therapeutics GmbH
14.3.10 Jiangsu HengRui Medicine Co., Ltd
14.3.11 Dova Pharmaceuticals, Inc
